ReShape Lifesciences Inc.
NASDAQ Capital MarketTotal Valuation
ReShape Lifesciences Inc. carries a market capitalization of 2.34M, placing it among publicly traded companies globally. Its enterprise value stands at -2.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.34M |
| Enterprise Value | -2.26M |
Share Statistics
ReShape Lifesciences Inc. currently has 451,049.00 shares outstanding.
| Shares Outstanding | 451,049.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.02, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 0.02 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.10 |
| P/FCF Ratio | -0.03 |
| P/OCF Ratio | -0.03 |
Enterprise Valuation
| EV / Sales | 0.81 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
ReShape Lifesciences Inc. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.53 |
| Quick Ratio | 0.79 |
| Debt / Equity | 10.57 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -47.07 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 0.54 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.87 |
Taxes
Over the trailing twelve months, ReShape Lifesciences Inc. has paid 33,000.00 in income taxes, reflecting an effective tax rate of 0.47.
| Income Tax | 33,000.00 |
| Effective Tax Rate | 0.47 |
Stock Price Statistics
ReShape Lifesciences Inc.'s stock has declined approximately -99.59712% over the past 52 weeks. The 50-day moving average sits at 10.51, while the 200-day moving average is 187.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.59712% |
| 50-Day Moving Average | 10.51 |
| 200-Day Moving Average | 187.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ReShape Lifesciences Inc. generated 7.18M in revenue and converted that into -3.46M in net income, yielding earnings per share of -254.30. EBITDA reached -6.28M, while operating income came in at -6.30M.
| Revenue | 7.18M |
| Gross Profit | 4.57M |
| Operating Income | -6.30M |
| Pretax Income | -3.43M |
| Net Income | -3.46M |
| EBITDA | -6.28M |
| EBIT | -6.30M |
| Earnings Per Share (EPS) | -254.30 |
Balance Sheet
ReShape Lifesciences Inc. holds 2.52M in cash and equivalents against 130,000.00 in total debt, resulting in a net debt position of -2.51M. Total book value stands at -641.23M, with working capital of 2.17M providing operational flexibility.
| Cash & Cash Equivalents | 2.52M |
| Total Debt | 130,000.00 |
| Net Debt | -2.51M |
| Equity (Book Value) | -641.23M |
| Book Value Per Share | -47,086.94 |
| Working Capital | 2.17M |
Cash Flow
ReShape Lifesciences Inc. produced -4.47M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.47M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.47M |
| FCF Per Share | -328.54 |
Margins
ReShape Lifesciences Inc. operates with a gross margin of 63.74, reflecting its pricing power and cost economics. The operating margin of -87.75 and net profit margin of -48.26 provide insight into operational efficiency.
| Gross Margin | 63.74 |
| Operating Margin | -87.75 |
| Pretax Margin | -47.80 |
| Profit Margin | -48.26 |
| EBITDA Margin | -87.47 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3,768.60 |
| FCF Yield | -3,646.35 |
Stock Splits
ReShape Lifesciences Inc.'s most recent stock split took place on August 15, 2025 with a 4:1 split ratio.
| Last Split Date | 8/15/2025 |
| Split Ratio | 4:1 |
Scores
ReShape Lifesciences Inc. posts an Altman Z-Score of -140.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -140.16 |